TABLE 4.

Proportions of subjects achieving Hib-PRP IgG GMCs and percentages of subjects achieving PRP IgG concentration of ≥0.15 μg/ml or ≥1.0 μg/ml 1, 2, 12, and 24 months following administration of Menitorix at 12 to 14 months of age

Time from administration of Menitorix (mo)	No. of subjects	GMC (95% CI)	% of subjects with PRP IgG concn of (95% CI):
			≥0.15 μg/ml	≥1.0 μg/ml
Preboosting	210	0.58 (0.49-0.69)	82 (76-87)	33 (27-40)
1	253	43.47 (36.56-51.70)	99 (97-100)	98 (96-100)
2	131	23.86 (18.75-30.38)	98 (95-100)	98 (93-100)
12	221	3.34 (2.82-3.96)	99 (96-100)	84 (79-89)
24	126	2.30 (1.87-2.84)	98 (94-100)	75 (67-83)